Indication: Lymphoma
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells
Sub-indication: Hematological Malignancies
Study Type: Specimen Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Sponsor: Celgene
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
